RxDoctor Payments Data

David Milkes, MD

Gastroenterology · Great Neck, NYNPI 1457375966

Payments from drug & device makers

$15,531in general payments, 2019–2025

Across 1,169 payments — averaging $13.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Bristol Myers Squibb$921
  • Pfizer$743
  • plus $5K from 36 others
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Speaking & faculty fees$200%
  • Grants$200%
  • Food & beverage$15,36599%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,531 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$395,324
Medicare patients
588
Services billed
6,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$306,613
XifaxanRifaximin48$133,156
RinvoqUpadacitinib13$100,285
LinzessLinaclotide81$79,861
TrulancePlecanatide47$36,396
Mesalamine39$32,585
CreonLipase/Protease/Amylase18$26,121
Dexlansoprazole DrDexlansoprazole31$12,578
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates128$7,414
Pantoprazole Sodium160$6,417
Ursodiol12$4,657
Colestipol Hcl71$3,297
Lubiprostone17$2,846
Famotidine175$2,123
Sucralfate28$2,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,911$306,61312 claims
AbbVieRinvoq, Linzess, Creon$3,771$206,267112 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,581$169,55195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →